Investors flocking to Spark Therapeutics Inc. more that doubled the company's value in a fiery debut that drove shares (NASDAQ:ONCE) of the gene therapy developer's upsized initial public offering (IPO) up 117.4 percent to $50 from its $23 initial offering price.